All News

Your daily dose of the clinical news you may have missed.

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

GX-03 has proven effective in preclinical trials, reducing disease severity by more than 50% vs placebo. Data from the current study are expected by year end.

Maternal depression significantly disrupts parenting behaviors, impacting child development and emotional bonding, according to an updated international literature review.

Lead author for the American College of Lifestyle Medicine's new clinical practice guideline discusses the broad endorsement for the recommendations across participating groups.

ENDO 2025. Older adults, rural populations, and residents in the Midwest experienced the highest mortality rates, according to new data.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

Treatment should address root causes, including lifestyle modifications, stress management, and gut health, Monu Khanna, MD, told Patient Care.

The abrupt cancellation, without warning or cause, has medical groups and health care leaders concerned about patient access to no-cost preventive services.

Jonathan Bonnet, MD, MPH, discusses common side effects of GLP-1 medications for obesity and how nutritional and behavioral strategies can help mitigate them.

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

Bayer's elinzanetant gains UK approval as the first dual-action, nonhormonal treatment for menopausal symptoms.

Lifestyle medicine integrates a spectrum of therapeutic lifestyle interventions best delivered by specialists who are often available to create a "virtual" team.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.